| Survival with olaparib in metastatic castration-resistant prostate cancer M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 383 (24), 2345-2357, 2020 | 562 | 2020 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 440 | 2021 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 213 | 2023 |
| Long-term outcome and prognostic factors in patients with cervical carcinoma: a retrospective study IL Atahan, C Onal, E Ozyar, F Yiliz, U Selek, F Kose International Journal of Gynecologic Cancer 17 (4), 2007 | 116 | 2007 |
| Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label … S Qin, M Chen, AL Cheng, AO Kaseb, M Kudo, HC Lee, AC Yopp, J Zhou, ... The Lancet 402 (10415), 1835-1847, 2023 | 54 | 2023 |
| Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation U Dişel, S Öztuzcu, AA Beşen, C Karadeniz, F Köse, AT Sümbül, A Sezer, ... Lung Cancer 71 (1), 109-112, 2011 | 36 | 2011 |
| Transfusion-associated graft-versus-host disease OA Oto, S Paydas, F Baslamisli, I Tuncer, M Ergin, E Kalakoc, U Disel, ... European Journal of Internal Medicine 17 (3), 151-156, 2006 | 33 | 2006 |
| Primary renal lymphoma: report of four cases F Kose, H Sakalli, H Mertsoylu, A Sezer, E Kocer, N Tokmak, F Kilinc, ... Oncology Research and Treatment 32 (4), 200-202, 2009 | 32 | 2009 |
| Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: the Baskent University experience F Kose, A Besen, T Sumbul, A Sezer, C Karadeniz, U Disel, O Altundag, ... Asian Pac J Cancer Prev 12 (5), 1185-1188, 2011 | 31 | 2011 |
| A study on basic demographic and disease characteristics of cancer-diagnosed Syrian refugees treated in the border city of Turkey, Sanliurfa; a hospital-based retrospective … YB Temi, AM Sedef, S Gokcay, H Coskun, SO Kaplan, O Ozkul, ... Breast cancer 57, 42.5, 2017 | 30 | 2017 |
| The effects of the nonsteroidal anti-inflammatory drug diclofenac sodium on the rat kidney, and alteration by furosemide A Besen, F Kose, S Paydas, G Gonlusen, T Inal, A Dogan, M Kibar, ... International urology and nephrology 41, 919-926, 2009 | 30 | 2009 |
| PID ve bulanık mantık ile DC motorun gerçek zamanda STM32F407 tabanlı hız kontrolü F Köse, K Kaplan, HM Ertunç Otomatik Kontrol Ulusal Toplantısı, TOK2013, 26-28, 2013 | 29 | 2013 |
| Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel AT Sümbül, A Sezer, H Abalı, F Köse, I Gültepe, H Mertsoylu, ... International urology and nephrology 46, 1531-1535, 2014 | 28 | 2014 |
| Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma Y Loriot, N Matsubara, SH Park, RA Huddart, EF Burgess, N Houede, ... New England Journal of Medicine 389 (21), 1961-1971, 2023 | 27 | 2023 |
| Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration‐resistant prostate cancer patients during abiraterone/enzalutamide treatment C Onal, F Kose, G Ozyigit, S Aksoy, E Oymak, S Muallaoglu, OC Guler, ... The Prostate 81 (9), 543-552, 2021 | 25 | 2021 |
| Squamous cell carcinoma of the renal pelvis F Kose, N Bal, O Ozyilkan Medical Oncology 26, 103-104, 2009 | 22 | 2009 |
| Primary extranodal non-Hodgkin's lymphoma: clinicopathological features, survival and treatment outcome in two cancer centers of southern Turkey H Mertsoylu, S Muallaoglu, AA Besen, S Erdogdu, A Sezer, AM Sedef, ... Asian Pacific Journal of Cancer Prevention 15 (17), 7207-7211, 2014 | 19 | 2014 |
| Colon adenocarcinoma and solitary tibia metastasis: rare entity F Kose, H Sakalli, A Sezer, H Mertsoylu, A Pourbagher, M Reyhan, ... Journal of gastrointestinal cancer 39, 146-148, 2008 | 19 | 2008 |
| Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial AO Siefker-Radtke, N Matsubara, SH Park, RA Huddart, EF Burgess, ... Annals of Oncology 35 (1), 107-117, 2024 | 18 | 2024 |
| Prevalence of thyroid dysfunction in untreated cancer patients: a cross-sectional study U Dişel, A Beşen, C Karadeniz, H Mertsoylu, A Sezer, F Köse, ... Medical Oncology 29, 3608-3613, 2012 | 16 | 2012 |
